Mali International Center for Excellence in Research: Malaria Clinical Research

顶点膜抗原1-组合1 (AMA1-C1)/醛水凝胶在马里儿童的1,2期研究完成。该双盲随机临床试验于2006年开始，于2008年1月完成临床随访。在donggubougou和Bancoumana两个地点共招募了336名儿童，并随访了两个疟疾传播季节，以评估这种血期疟疾候选疫苗的安全性和对恶性疟疾的生物学影响。2007年11月在美国热带医学与卫生学会上公布了第一个传播季节的结果。

Completion of a Phase 1,2 study of Apical Membrane Antigen 1-Combination 1 (AMA1-C1)/Alhydrogel in Malian children. This double blind, randomized clinical trial started in 2006 and completed clinical follow up in January 2008. A total of 336 children were enrolled in two sites (Dongubougou and Bancoumana) and followed through two malaria transmission seasons to assess the safety and biologic impact on falciparum malaria of this blood stage malaria vaccine candidate. Results through the first transmission season were presented at the American Society of Tropical Medicine and Hygiene in November 2007. Initiation and completion of a Phase 1 study of AMA1-C1/Alhydrogel + CPG 7909 in Malian adults. This was a double blind, randomized clinical trial of AMA1-C1/Alhydrogel, with the novel adjuvant CPG 7909, which has been shown in a previous US trial to enhance antibody responses to vaccination 10-14 fold. This was the first use of CPG 7909 in a malaria endemic population. Vaccinations began in October 2007 and follow up was completed in May 2008. Safety data from this study have laid the foundation for a Phase 1 study of the same vaccine in Malian children, expected to begin in October, 2008. Epidemiologic study in Malian infants. This study enrolled 100 infants (aged 6 weeks to 6 months) in August 2007 and followed them through a malaria transmission season to January 2008. Another 100 infants were enrolled in July 2008, and will be followed through two malaria transmission seasons. Data obtained will be used to establish baseline parameters and sample size estimates for anticipated Phase 2 trials of malaria vaccine candidates in Malian infants. Laboratory. Clinical and immunologic lab staffing, equipment, and procedures were comprehensively assessed and strengthened. Results are now continuously validated, and quality of data produced by the lab is comparable to that produced at the MIV.